Don’t miss the latest developments in business and finance.

Astrazeneca Pharma spurts after turnaround in Q3

Image
Capital Market
Last Updated : Feb 11 2014 | 11:59 PM IST

Astrazeneca Pharma India surged 12.71% to Rs 833 at 10:29 IST on BSE after the company reported a net profit of Rs 1.52 crore in Q3 December 2013 as against net loss of Rs 17.70 crore in Q3 December 2012.

The Q3 result was announced after market hours on Monday, 10 February 2014.

Meanwhile, the S&P BSE Sensex was up 66.20 points or 0.33% at 20,400.47.

On BSE, so far 80,000 shares were traded in the counter as against average daily volume of 4,596 shares in the past one quarter.

The stock hit a high of Rs 846.80 and a low of Rs 757.25 so far during the day. The stock had hit a 52-week high of Rs 1,308.20 on 12 February 2013. The stock had hit a 52-week low of Rs 595 on 26 March 2013.

The stock had underperformed the market over the past one month till 10 February 2014, sliding 9.15% compared with the Sensex's 2.04% fall. The scrip had also underperformed the market in past one quarter, declining 15.51% as against Sensex's 1.61% fall.

More From This Section

The small-cap company has equity capital of Rs 5 crore. Face value per share is Rs 2.

Astrazeneca Pharma India's net sales rose 13.3% to Rs 118.88 crore in Q3 December 2013 over Q3 December 2012.

AstraZeneca Pharma India is one of the world's leading pharmaceutical companies, with a broad range of medicines designed to fight disease in important areas of healthcare. The company is involved in both manufacturing and marketing of medicines.

Powered by Capital Market - Live News

Also Read

First Published: Feb 11 2014 | 10:32 AM IST

Next Story